Dr. Ofer Sharon is a physician and entrepreneur with 20 years of experience in clinical and commercial product development for startups in the health tech, biotech, and medical device industries. Prior to joining OncoHost, he served multiple roles in global pharmaceutical companies including Medical Director for AstraZeneca (Israel), new technologies scout for MedImmune, and Medical Director for MSD (Israel). He co-founded several healthcare companies, mainly focusing on bioinformatic and machine-learning platforms for clinical deterioration detection and early intervention. Dr. Sharon received his MD cum laude from Tel Aviv University, Israel.
Ofer Sharon, MD
Steven M. Gottlieb, M.D. is a physician executive and healthcare serial entrepreneur with over 30 years of experience in the healthcare industry. He completed his specialty training in anesthesiology, pain management, and critical care medicine at The Johns Hopkins Hospital. He has founded, managed, funded, grown and exited several successful healthcare companies. Dr. Gottlieb has served on numerous boards of directors and in various leadership positions within hospital, community, corporate and professional organizations. His board positions (chairman, member or advisory) have included Medical Center Boards of Trustees, County Board of Health, EGPG, Anthem Associates, Anesthetix Holdings, Billing Management, Coagulo Medical Technologies, TruVue Analytics, Katao Venture Partners, Temple University, First City Bank of Commerce and the Palm Beach Round Table. Dr. Gottlieb has led or participated in a range of successful investments in a variety of growth companies, both inside and outside of the healthcare industry. Dr. Gottlieb currently serves as Chairman of Javelin10x, an organization that functions as a strategic operating partner to entrepreneurial companies and helps accelerate their growth and success.
Steven Gottlieb, MD
Prof. Yuval Shaked leads an academic research laboratory at the Rappaport Faculty of Medicine of the Technion–Israel Institute of Technology. His pioneering research, which focuses on understanding tumor-host interactions and therapy-induced mechanisms of tumor progression, serves as the scientific basis for OncoHost’s technology. Prof. Shaked is currently head of the Technion Integrated Cancer Center and President of the International Cancer Microenvironment Society. Formerly, he served as Vice Dean for Research at the Rappaport Faculty of Medicine of the Technion. In addition, he is a member of several cancer societies, including the American Association for Cancer Research (AACR), the European Association of Cancer Research (EACR), and the Israel Society of Cancer Research (ISCR). Prof. Shaked is the author and co-author of over 100 peer-reviewed publications and 5 patents and a recipient of multiple competitive research grants including the prestigious European Research Council (ERC) grants. For his achievements, he has received numerous awards including the Igal Alon fellowship award for starting junior faculty, the Krill Prize for Excellence in Scientific Research, and the Youdim Family Prize for Excellence in Cancer Research. He received his Ph.D. in biochemistry from the Hebrew University of Jerusalem, Israel, and completed his post-doctoral training at Sunnybrook Health Sciences Centre, University of Toronto, Canada.
Yuval Shaked, PhD
Co-Founder & Chief Scientific Advisor
Dr. Dicker is Professor, Radiation Oncology, Pharmacology, Systems Physiology, and Cancer Biology at Sidney Kimmel Medical College and Cancer Center at Thomas Jefferson University-Jefferson Health, Philadelphia, PA. Dr. Dicker is a leading prostate cancer expert focusing on computational oncology and founded the Jefferson Center for Digital Health & Data Science. His work has resulted in establishing parameters for quality assurance in oncology, novel therapeutic clinical trials utilizing targeted therapies, innovative models to evaluate radiation modifiers, FDA approval of a genomic signature for the management of prostate cancer, and the use of wearables combined with patient-reported outcomes to identify and mitigate cancer treatment toxicity. His funded research examines patient-reported outcome development for molecular targeted radiopharmaceuticals and machine and deep learning architectures to identify factors associated with toxicity and quality of life in men with locally advanced prostate cancer. He has published numerous textbooks in oncology and has over 350 publications. He serves on several National Cancer Institute committees and other oncology organizations. He was elected a Fellow of the American Society of Radiation Oncology and the American Society of Clinical Oncology. Dr. Dicker received his BA from Columbia College and MD and PhD (Molecular Pharmacology) from Weill Cornell Medical College and Weill Cornell School of Medical Sciences of Cornell University, respectively. After a surgical internship, he received his postgraduate training in radiation oncology at Memorial Sloan-Kettering Cancer Center.
Adam Dicker, MD, PhD
Chief Medical Officer
Dr. Shani Raveh Shoval has 15 years of experience in biological research and intellectual property. Prior to joining OncoHost, she was a project manager at Pluristem Therapeutics and an intellectual property manager at Enzymotec. Dr. Shoval holds a Ph.D. in molecular and cellular biology from the Weizmann Institute of Science.
Shani Raveh Shoval, PhD
VP Clinical Affairs
Moti Hacham has over 20 years of versatile senior management, operational, financial, and legal experience in the biotech industry, including positions at Spero Bio (CEO), Avraham Pharma (CFO & COO), Polyheal (COO), CureTech (CFO) and Clal Life Sciences (CEO). Previously an attorney at a leading law firm, and assistant to the CFO of Check Point Software Technologies (NASDAQ: CHKP). Moti holds a BA in Economics from Tel-Aviv University and an LLB from Bar-Ilan University. He is a member of the Israeli Bar Association.
Moti Hacham, LLB
Dr. Yehonatan Elon has over 10 years of experience in the data and algorithms industry, with a proven track record in end-to-end product development. Dr. Elon holds a PhD in physics from the Weizmann Institute of Science, was director of new technologies at BrightSource Energy, and VP of Research at MeteoLogic and Feedvisor.
Yehonatan Elon, PhD
Dr. Itamar Sela is a multidisciplinary scientist specializing in mathematical modeling and data analysis, with extensive experience in physics and computational biology. Prior to joining OncoHost, he was a postdoctoral fellow at the National Institutes of Health in Maryland USA, where he developed a theoretical framework to study quantitatively bacterial genome evolution. Dr. Sela received his Ph.D. in theoretical physics from Ben-Gurion University, followed by R&D positions in the industry and post-doctoral training.
Itamar Sela, PhD
Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in Marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.
Chris Dingman, MBA
Dr. Michal Harel has over 8 years of experience in OMIC-level bioinformatic analysis, with strong expertise in working with proteomics data. Prior to joining OncoHost, Dr. Harel worked as a research associate at Tel Aviv University. She received her Ph.D. from the Weizmann Institute of Science and a post-doctoral at the Technion–Israel Institute of Technology.
Michal Harel, PhD
Director of Science and Innovation
Ayelet has over 15 years of experience in leading medical system implementation, product management, business analysis, programming, and customer consulting in the healthcare industry. Prior to joining OncoHost, she was implementation lead at Algotec, professional services manager, product manager at EarlySign, and product and project manager at Kamet. Ayelet holds an ME in Biomedical Engineering from the Technion Institute of Technology.
Ayelet Ran, ME
Head of Product
Oshrit began her healthcare career at a leading global biopharmaceutical company, where she served as a vital member of the medical team overseeing the compassionate use programs. She later transitioned to OncoHost as a Clinical Research Associate, dedicating three years to impactful research. In 2022, Oshrit assumed the role of Head of HR, focusing on the wellbeing of OncoHost's team members. Oshrit is a dedicated volunteer at the "First Hug Association," providing crucial support to abandoned and lonely babies for the past three years. Oshrit holds a BA in Arab Language and Middle Eastern Studies from the Hebrew University of Jerusalem, an MA in Public Administration from Tel Aviv University, and a diploma in Human Resource Management from Bar Ilan University.
Oshrit Regev Rokach
Head of HR
Shlomi is a highly experienced healthcare executive with a 15-year track record in the life sciences and healthcare sectors. Throughout his career, he has collaborated with prominent healthcare and pharmaceutical organizations, guiding them toward becoming data-driven entities that foster innovation and achieve success through evidence-based insights and analytics. In addition, Shlomi has spearheaded customer success and partnership teams at numerous biotech and healthcare startups, contributing to clinical development initiatives and the co-discovery of therapeutic assets. Holding a Ph.D. in Molecular Biology from the Weizmann Institute, Shlomi has co-authored over 25 scientific publications and holds a patent for cancer treatment.
Shlomi Madar, PhD
VP Strategic Alliances
Ben is a physicist and data scientist. He previously worked as the CTO of Asana Bio Group and as a strategic and scientific consultant at Deloitte. Ben received his M.Sc. and Ph.D. in Theoretical and Mathematical Physics from Ben-Gurion University of the Negev. He completed his post-doc at the Technion - Israel Institute of Technology, where his team developed a novel physical modeling and experimental assay for human cell motility and cancer metastasis, and built statistical models for self-reported medical data and clinical trials.
Ben Yellin, PhD
Director of R&D
Amir has over 15 years of experience in assay development, biochemistry, molecular cell biology, and medical diagnostics. Before joining OncoHost, Amir worked as a senior assay development scientist and a project manager at MeMed Dx, where he gained vast experience in the development of a plasma-based biochemical assay, integrating it on a point-of-care IVD medical device, all the way from proof of concept to an FDA-cleared product. He later led a multidisciplinary project to launch yet another FDA-cleared test, this time in whole blood. He completed his B.Sc. at The Hebrew University of Jerusalem, and his M.Sc. and Ph.D. at the Weizmann Institute of Science.
Amir Gelman, PhD
Director of Laboratory Operations & Assay Development
Anna is an experienced nurse practitioner with extensive oncology and critical care experience, as well as training in public health. Previously, Anna has worked at the U.S. Embassy as a Registered Nurse/Emergency Medical Preparedness Coordinator, at MD Anderson Cancer Center in their emergency department as a registered nurse, and at Tampa General Hospital as a nurse practitioner. Anna completed her MPH at Tel Aviv University, and her MSN, Family Nurse Practitioner, at The University of Texas Medical Branch.
Anna Manasherov, MSN, MPH
Director of Clinical Oncology
David Gandara is a Professor of Medicine Emeritus at the University of California, Davis. He is the co-director of the Center for Experimental Therapeutics and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct Clinical Professor of the Translational and Clinical Research Program at the University of Hawaii Cancer Center and Chief Medical Officer for the International Society of Liquid Biopsy (ISLB), a non-profit organization dedicated to advancing the science and clinical application of liquid biopsy in cancer diagnosis and therapy. He is an internationally known clinician-scientist and lung cancer thought leader and has published over 450 peer-reviewed papers. He has led many notable research projects in lung cancer, including early therapeutics trials through an N01-sponsored award, cooperative group trials as past-chair of the SWOG Lung Committee, and multi-institutional translational science projects such as clinical director of the patient-derived xenograft (PDX) lung program in collaboration with The Jackson Laboratory Cancer Center. Dr. Gandara has been selected for many awards and honors, including the Lifetime Scientific Award from the International Association for Study of Lung Cancer (IASLC), the Team Science Award from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from the ISLB. He is current principal investigator for a National Cancer Institute UG1 award to UCDCCC for cancer clinical trials, and co-leader of Lung-MAP, a unique NCI-sponsored public-private partnership for new drug development in lung cancer. He is the founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). Dr. Gandara is the past Editor-in-Chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara received the Giants of Cancer Care Award for lung cancer.
David R. Gandara, MD
David Carbone is a Professor of Internal Medicine and Director of the James Thoracic Oncology Center at the OSUMC. He graduated summa cum laude from Amherst College in 1977 and received an MD and a Ph.D. in Molecular Biology and Genetics at Johns Hopkins University in 1985. After an Internal Medicine internship and residency at The Johns Hopkins Hospital, he did a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. At Vanderbilt, he was Director of the Thoracic/Head and Neck Cancer Program, Director of a SPORE in Lung Cancer for 11 years. He was recruited to The Ohio State University in 2012 to direct the James Thoracic Oncology Center. His research interests have been focused on lung cancer and specifically proteomic and expression signature development, lung cancer genetics, tumor-associated immunosuppression mechanisms, proteogenomic profiling of lung cancers to guide the development of novel therapeutics, and targeting novel immunosuppression mechanisms. He has over 250 peer-reviewed publications, has served on the Board of Scientific Counselors, and has had continuous NCI funding since early in his career. He is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and past President of the International Association for the Study of Lung Cancer (IASLC).
David Carbone, MD, PhD
Dr. Hirsch is a medical oncologist with training in pathology. He is a Professor in Medicine and Pathology at Icahn School of Medicine and Executive Director for the Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai, NY. His interest is lung cancer research, with special emphasis on new treatments, biomarker development, and validation for treatment and early detection of lung cancer. Dr. Hirsch's lab focuses on selecting patients for new targeted therapies, particularly in lung cancer (personalized medicine). He is the principal investigator of many clinical trials and a study chair for correlative science in the Lung Masterprotocol (LungMAP). Finally, he co-chairs the Lung Group (translational science) for the Southwest Oncology Group (SWOG). Dr. Hirsch has published over 400 scientific publications.
Fred R. Hirsch, MD, PhD
Dr. Lee Ellis is a translational investigator primarily focused on GI cancers. He has served in leadership roles in ASCO (BOD), AACR, NCI, EORTC (Scientific Audit Comm), ESMO/TAT, JAMA Oncology (Deputy Editor), and MD Anderson Cancer Center. He is a leader in SWOG as Vice Chair for Translational Medicine and co-chaired the inaugural NCI NCTN-Core Correlative Sciences Committee. Dr. Ellis serves on several data monitoring committees including ECOG-ACRIN. He is a member of the inaugural AACR "Trust in Science Task Force", and serves on the ELEVATE GENETICS Acceptable Thresholds Committee representing ASCO. He is also an officer of ESMO where he serves on their COI committee.
Lee M. Ellis, MD, FACS, FASCO
Timothy Chan, MD, PhD, a renowned immuno-oncology and cancer genomics expert, leads the Center for Immunotherapy and Precision Immuno-Oncology, which brings together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related to the rapidly growing field of immuno-oncology. He is an internationally recognized expert in precision immuno-oncology and a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He has published over 200 articles in peer-reviewed journals, made landmark discoveries in his field and received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018. Dr. Chan earned his MD and PhD in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology. He is board certified in radiation oncology and is an elected member of the Association of American Physicians. Dr. Chan also collaborates with experts in the Center for Global and Emerging Pathogens Research, which is focused on broadening understanding of immunology and microbial pathogenesis with the goal of improving treatment for a variety of diseases, including virus-induced cancers.
Timothy Chan, MD, PhD
Prof. Michal Lotem is a senior physician and researcher, serving as Head of the Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah University Hospital, and senior lecturer at the Faculty of Medicine, Hebrew University of Jerusalem. In parallel to intensive clinical work, she runs a scientific translational research lab focusing on tumor vaccines and cell-based immunotherapies for melanoma. She has co-authored over 70 peer-reviewed publications and is a member of several medical societies including the Melanoma Research Alliance, Society of Melanoma Research, European Association of Cancer Research (EACR), Israel Society of Cancer Research (ISCR) and Committee for Cell and Gene-based Therapy of the Israeli Ministry of Health. Prof. Lotem received her MD from the Sackler Faculty of Medicine at Tel Aviv University, Israel, and was a research fellow at the National Institute of Health (NIH), Maryland, USA.
Michal Lotem, MD
Dr. Mario Sznol is a Professor of Internal Medicine, Leader of the Melanoma-Renal Cancer Disease-Associated Translational Research Team, and Co-Leader of the Cancer Immunology Program. Dr. Sznol is also the current President of the Society for Immunotherapy of Cancer (SITC). Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, at Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), and Cancer Therapy Evaluation Program of the National Cancer Institute. He was Head of the BES from 1994-1999. He attended the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut. Dr. Sznol’s areas of interest include early drug development, immunotherapy, and treatments for advanced melanoma and renal cancer.
Mario Sznol, MD
Prof. Ciechanover is a distinguished research professor in the Rappaport Faculty of Medicine at the Technion–Israel Institute of Technology in Haifa, Israel, and serves on the board of several biotech companies. His current research is focused on several biological aspects of cancer development and tumor suppression, involving the role of the ubiquitin-proteasome system in these processes. His laboratory, which is part of the Rappaport Technion’s Integrated Cancer Center (RTICC) in the Rappaport Faculty of Medicine, is currently involved in the development of several anti-cancer drugs – including a unique PROTAC. It expands its areas of research and focus to include informatics, AI-based diagnostic tools, and metabolomics, and in collaboration with Oncology Centers in Israel and China, initiating clinical trials that use the application of precision medicine for the benefit of cancer patients. Among the many accolades that Prof. Ciechanover has been awarded are the 2000 Albert Lasker Prize for Basic Medical Research, the 2003 Israel Prize for Biological Research, and the 2004 Nobel Prize in Chemistry. He is a member of various academies, including the Israeli National Academy of Sciences and Humanities, the European Molecular Biology Organization (EMBO), the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), and the Chinese Academy of Sciences (CAS; Foreign Member).
Aaron Ciechanover, MD, DSC
Prof. Raanan Berger is a senior oncologist and radiotherapist, serving as Director of the Cancer Center at the Sheba Medical Center, Israel. In 2006, he established the Riva Koschitzky Oncology Clinical Research Unit at Sheba, the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials. In addition, he is a senior lecturer at the Sackler Medical School at Tel Aviv University and runs a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis. Prof. Berger is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), and co-author of over 70 peer-reviewed scientific articles. He received his MD and PhD from the Sackler Faculty of Medicine at Tel Aviv University, Israel, and was a post-doctoral fellow at Dana Farber Cancer Institute, Harvard Medical School.
Ra'anan Berger, MD, PhD
Prof. Robert Kerbel is a distinguished scientist at Sunnybrook Health Sciences Centre, University of Toronto, Canada. He is internationally recognized for his multiple contributions to cancer research, particularly in the fields of anti-angiogenic therapy and metronomic chemotherapy. For his achievements, Prof. Kerbel has been awarded the Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology, a Man of Distinction Honor by the Israel Cancer Research Fund, and the Colin Thomson Memorial Medal from Worldwide Cancer Research. He was a recipient of a tier 1 Canada Research Chair in Tumor Biology, Angiogenesis, and Antiangiogenic Therapy from 2001-2015. Prof. Kerbel is a member of numerous scientific advisory boards in both industry and academia as well as scientific peer review journal editorial boards. He also holds multiple sponsored research agreements with biotech and pharmaceutical companies. Prof. Kerbel received his PhD in immunology from Queen’s University in Kingston, Ontario, Canada in 1972, and completed postdoctoral training in tumor immunology at the Chester Beatty Research Institute in London, England.
Robert Kerbel, PhD
Prof. Domany works in the faculty of Complex Systems Physics at the Weizmann Institute of Science. His expertise is in the field of statistical physics. His current research interests focus on the development of computational methods, with a special emphasis on applications to biologically motivated problems, in particular, analysis of high-throughput biological data. He works with several groups from the life sciences, in Israel and abroad, on analysis of human gene expression data obtained from DNA chips, with an emphasis on studies of cancer. Winner of the Lombroso Award in Cancer Research.
Eytan Domany, PhD